CRISTINA CARRERA

Dr. CRISTINA CARRERA

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Nature
Verified
Journal Article
Closed access
PDF file
AHAlexander C. Huang
Alexander C. Huang
MPMichael A. Postow
Michael A. Postow
RORobert J. Orlowski
Robert J. Orlowski
RMRosemarie Mick
Rosemarie Mick
BBBertram Bengsch
Bertram Bengsch
EWE. John Wherry
E. John Wherry

1 February 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
MMMichael A. Marchetti
Michael A. Marchetti
NCNoel C.F. Codella
Noel C.F. Codella
SDStephen W. Dusza
Stephen W. Dusza
DGDavid A. Gutman
David A. Gutman
BHBrian Helba
Brian Helba
AHAllan C. Halpern
Allan C. Halpern

20 April 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Giuseppe ArgenzianoGiuseppe Argenziano
Giuseppe Argenziano
SPSusana Puig
Susana Puig
IZIris Zalaudek
Iris Zalaudek
FSFrancesco Sera
Francesco Sera
RCRosamaria Corona
Rosamaria Corona
JMJosep Malvehy
Josep Malvehy
Purpose: Primary care physicians (PCPs) constitute an appropriate target for new interventions and educational campaigns designed to increase skin cancer screening and prevention. The aim of this randomized study was to determine whether the adjunct of dermoscopy to the standard clinical examination improves the accuracy of PCPs to triage lesions suggestive of skin cancer. Patients and Methods: PCPs in Barcelona, Spain, and Naples, Italy, were given a 1-day training course in skin cancer detection and dermoscopic evaluation, and were randomly assigned to the dermoscopy evaluation arm or naked-eye evaluation arm. During a 16-month period, 73 physicians evaluated 2,522 patients with skin lesions who attended their clinics and scored individual lesions as benign or suggestive of skin cancer. All patients were re-evaluated by expert dermatologists at clinics for pigmented lesions. Referral accuracy of both PCP groups was calculated by their scores, which were compared to those tabulated for dermatologists. Results: Referral sensitivity, specificity, and positive and negative predictive values were 54.1%, 71.3%, 11.3%, and 95.8%, respectively, in the naked-eye arm, and 79.2%, 71.8%, 16.1%, and 98.1%, respectively, in the dermoscopy arm. Significant differences were found in terms of sensitivity and negative predictive value (P = .002 and P = .004, respectively). Histopathologic examination of equivocal lesions revealed 23 malignant skin tumors missed by PCPs performing naked-eye observation and only six by PCPs using dermoscopy (P = .002). Conclusion: The use of dermoscopy improves the ability of PCPs to triage lesions suggestive of skin cancer without increasing the number of unnecessary expert consultations.

13 September 2014 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KGKlaus G. Griewank
Klaus G. Griewank
RMRajmohan Murali
Rajmohan Murali
JPJoan Anton Puig-Butille
Joan Anton Puig-Butille
BSBastian Schilling
Bastian Schilling
ELElisabeth Livingstone
Elisabeth Livingstone
DSDirk Schadendorf
Dirk Schadendorf
Recently, TERT promoter mutations were identified at high frequencies in cutaneous melanoma tumor samples and cell lines. The mutations were found to have a UV-signature and to lead to increased TERT gene expression. We analyzed a large cohort of melanoma patients for the presence and distribution of TERT promoter mutations and their association with clinico-pathological characteristics. 410 melanoma tumor samples were analyzed by Sanger sequencing for the presence of TERT promoter mutations. An analysis of associations between mutation status and various clinical and pathologic variables was performed. TERT promoter mutations were identified in 154 (43%) of 362 successfully sequenced melanomas. Mutation frequencies varied between melanoma subtype, being most frequent in melanomas arising in nonacral skin (48%) and melanomas with occult primary (50%), and less frequent in mucosal (23%), and acral (19%) melanomas. Mutations carried a UV signature (C>T or CC>TT). The presence of TERT promoter mutations was associated with factors such as BRAF or NRAS mutation (P < .001), histologic type (P = .002), and Breslow thickness (P < .001). TERT promoter mutation was independently associated with poorer overall survival in patients with nonacral cutaneous melanomas (median survival 80 months vs 291 months for wild-type; hazard ratio corrected for other covariates 2.47; 95% confidence interval [CI] = 1.29 to 4.74; P = .006). UV-induced TERT promoter mutations are one of the most frequent genetic alterations in melanoma, with frequencies varying depending on melanoma subtype. In nonacral cutaneous melanomas, presence of TERT promoter mutations is independently associated with poor prognosis.

1 July 2012 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
GSGabriel Salerni
Gabriel Salerni
CCCRISTINA CARRERA
CRISTINA CARRERA
LLLouise Lovatto
Louise Lovatto
JBJoan Anton Puig Butillé
Joan Anton Puig Butillé
CBCelia Badenas
Celia Badenas
JMJosep Malvehy
Josep Malvehy

1 August 2009 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
SSSonia Segura
Sonia Segura
SPSusana Puig
Susana Puig
CCCRISTINA CARRERA
CRISTINA CARRERA
JPJosep Palou
Josep Palou
JMJosep Malvehy
Josep Malvehy